Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback